NCT lookup

Inclusion Criteria:

1. Cluster eligibility

   * Within 8 hours transport of Iquitos
   * Incidence \<250/1000 and \>2 cases year prior to trial
   * Population size (\<650)
2. Chloroquine (CQ) eligibility

   * Resides in neighboring household but within 200 m of Pv index case in the past 2 years
   * Age ≥6 months old
   * Present for intervention
   * Adult ≥18 years old that provides informed consent
   * A child ≥8 years and \<18 years old that provides informed assent and has informed consent from their parents
   * A child ≥6 months old and \<8 years old that has informed consent from their parents
3. Tafenoquine (TQ) eligibility

   * Eligible to receive CQ
   * Age ≥16 years old
   * Adult ≥18 years old that provides informed consent
   * A child ≥16 years and \<18 years old that provides informed assent and has informed consent from their parents
4. Primaquine eligibility

   * Eligible to receive CQ and ineligible to receive TQ
   * Age ≥6 months old
   * Adult ≥18 years old that provides informed consent
   * A child ≥8 years and \<18 years old that provides informed assent and has informed consent from their parents
   * A child ≥6 months old and \<8 years old that has informed consent from their parents
5. Baseline evaluation and informed consent

   -Villagers will be eligible to participate in surveys if they slept in a household in cluster randomized to control or focal mass drug administration (fMDA) for at least one night in the past four weeks
6. Eligibility for fMDA

   * High-risk villagers are defined as individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household) will be eligible to receive fMDA that cycle
   * Villagers that were eligible but missed in the 1st round in a cycle, or become eligible in the next two months, will not be eligible to receive fMDA in the 2nd round in a cycle.

Exclusion Criteria:

1. Chloroquine eligibility

   * History of retinal or visual field changes
   * Known hypersensitivity or adverse reaction to CQ
   * Currently taking CQ or have taken CQ in the past four weeks
   * Ineligible for TQ or PQ (see criteria below)
   * Hemoglobin \<9 g/dL
2. Tafenoquine eligibility

   * G6PD deficiency or intermediate status (defined as activity ≤6.0 UI/gHb per SD biosensor)
   * G6PD status unknown or refusal of G6PD status test
   * Acute or severe malaria
   * Pregnancy (known or identified by pregnancy test)
   * Refusal of pregnancy test if new amenorrhea in the past 4 weeks
   * Woman breastfeeding a child that is G6PD deficient or with unknown G6PD status
   * Known hypersensitivity or adverse reaction to TQ or PQ
   * Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks
   * Hemoglobin \< 9 g/dL
3. Primaquine eligibility

   * G6PD deficiency (defined as activity ≤4.0 UI/gHb per SD biosensor)
   * G6PD status unknown or refusal of G6PD status test
   * Acute or severe malaria
   * Pregnancy (known or identified by pregnancy test)
   * Refusal of pregnancy test if new amenorrhea in the past 4 weeks
   * Breastfeeding child with documented or unknown G6PD deficiency status
   * Woman breastfeeding a child with documented or unknown G6PD deficiency status
   * Known hypersensitivity or adverse reaction to TQ or PQ
   * Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks
   * Hemoglobin \< 9 g/dL

• Iquitos, Peru